심혈관 질환 유병률 증가, 생활습관병 유병률 증가, 인식 개선 및 스크리닝 프로그램, 세계 주요 기업의 제품 개발 활동 증가로 인해 2032년까지 안정적인 CAGR로 성장할 것으로 예측됩니다.
아테렉토미 디바이스 시장 규모는 2024년 10억 4,594만 달러에서 예측 기간 중 CAGR 9.05%로 추이하며, 2032년에는 20억 8,337만 달러에 달할 것으로 예측됩니다. 당뇨병, 비만 등 심혈관 질환 및 생활습관병의 유병률 증가는 죽상동맥경화증 치료를 위한 죽상동맥경화증 치료용 동맥경화증 치료기기 수요를 촉진하고 있습니다. 또한 동맥폐색에 대한 의식의 향상와 스크리닝 프로그램이 동맥폐색 조기 발견 및 진단으로 이어지면서 동맥절제술에 대한 수요가 증가하고 있습니다. 또한 주요 업체들의 아테렉토미 기술의 발전으로 정확성과 안전성이 향상되어 복잡한 환자 치료에 더욱 효과적일 수 있게 되었습니다. 이러한 요인들이 복합적으로 작용하여 세계 아테렉토미 디바이스 시장의 성장에 박차를 가하고 있습니다. 이러한 요인들을 종합하면 2025-2032년까지의 예측 기간 중 아테렉토미 디바이스 시장을 촉진할 것으로 예측됩니다.
아테렉토미 디바이스 시장 역학:
영국 심장재단(British Heart Foundation)의 2025년 자료에 따르면 전 세계에서 약 6억 4,000만 명, 약 12명 중 1명이 심장 및 순환기 질환을 앓고 있습니다.
또한 재단의 2024년 자료에 따르면 세계에서 가장 흔하게 진단되는 관상동맥성 심장질환(허혈성 심장질환)은 약 2억 명이 앓고 있으며, 그 중 남성이 약 1억 1,000만 명, 여성이 약 8,000만 명으로 추산됩니다. 또한 뇌졸중 생존자는 여성 약 5,600만 명, 남성 약 4,500만 명으로 보고되고 있습니다. 선천성 심장병은 최소 1,300만 명이 앓고 있는 것으로 추정되며, 진단되지 않은 환자도 수백만 명에 달할 것으로 추정됩니다. 심혈관 질환(CVD)은 동맥 내에 플라크가 쌓여 동맥이 좁아지거나 막히는 동맥경화증을 유발하는 경우가 많아 효과적인 치료법의 필요성이 대두되고 있습니다. 죽상동맥경화증 치료기는 이러한 플라크를 제거하고 혈류를 회복시켜 관상동맥질환 및 말초동맥질환 관리에 필수적인 역할을 하고 있습니다. 따라서 죽상동맥경화증은 심근경색, 뇌졸중, 말초동맥질환, 심장마비 등의 질환의 주요 원인으로 알려져 있으며, 이러한 심각한 심혈관 질환으로의 진행을 예방하기 위해서도 죽상동맥경화증 치료는 매우 중요하며, 죽상동맥경화증 치료기기의 사용이 보편화되어 있습니다. 따라서 심혈관 질환의 유병률 증가는 동맥경화증 치료기기에 대한 수요 증가로 이어져 예측 기간 중 시장 성장에 기여할 것으로 보입니다.
또한 최소침습적 장치 및 시술에 대한 수요 증가는 죽상동맥경화증 장치 시장의 성장을 가속하는 또 다른 중요한 요인으로 작용하고 있습니다. 이는 기존 수술법에 비해 빠른 치유 속도와 신체에 대한 부담이 적은 저침습적 접근법에 따른 장점이 널리 인식되고 있기 때문입니다. 방향성 죽종절제술과 같은 죽종절제술은 스텐트와 같은 삽입형 장치를 사용하지 않고 폐쇄성 내막비후성 병변이나 죽종성 병변을 제거할 수 있는 저침습적 치료법으로 평가받고 있습니다. 또한 죽상동맥경화술은 외과적 수술로 인한 흉터나 염증과 같은 부작용을 피할 수 있으며, 향후 죽상동맥경화술 시장의 성장을 더욱 촉진할 것으로 기대됩니다.
또한 주요 기업의 전략적 노력과 기술 혁신의 발전도 시장의 세계 확대에 기여하고 있습니다. 위와 같은 요인으로 인해 예측 기간 중 전 세계에서 시장이 성장할 것으로 예측됩니다.
세계의 아테렉토미 디바이스 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회의 분석, 법규제 환경, 시장 규모 추이·예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.
Atherectomy Devices Market by Product Type (Directional, Rotational, Photoablative, and Orbital), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of cardiovascular diseases, increase in prevalence of lifestyle disorders, rising awareness and screening programs, and increase in product development activities by key market players across the globe.
The atherectomy devices market was valued at USD 1,045.94 million in 2024, growing at a CAGR of 9.05% during the forecast period from 2025 to 2032, to reach USD 2,083.37 million by 2032. The rising prevalence of cardiovascular diseases and lifestyle disorders, such as diabetes and obesity, is driving the demand for atherectomy devices to treat atherosclerosis. Additionally, growing awareness and screening programs have led to earlier detection and diagnosis of arterial blockages, resulting in higher demand for atherectomy interventions. Furthermore, the advancements in atherectomy technology by key market players are improving precision and safety, making these devices more effective in treating complex cases. Together, these factors are fueling the growth of the global atherectomy device market. Collectively, these factors are expected to boost the market for atherectomy devices during the forecast period from 2025 to 2032.
Atherectomy Devices Market Dynamics:
According to recent data provided by the British Heart Foundation (2025), globally, approximately 640 million people, or about 1 in 12 individuals, live with heart and circulatory diseases.
Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, the most commonly diagnosed worldwide, affected an estimated 200 million people globally of which 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed. As CVD often leads to conditions like atherosclerosis, where plaque buildup narrows or blocks arteries, the need for effective treatments is rising. Atherectomy devices, which remove plaque and restore blood flow, are becoming essential in managing conditions such as coronary artery disease and peripheral artery disease. Thus, atherosclerosis is considered a major cause of myocardial infarctions, strokes, peripheral arterial disease, and heart attack. To avoid the progression to other serious CVDS, treatment of atherosclerosis becomes imperative wherein the application of atherectomy devices has become a norm. Therefore, the increase in the prevalence of cardiovascular diseases is projected to result in the growing demand for atherectomy devices, thereby contributing to the growth of the atherectomy devices market during the forecast period.
Moreover, another key factor that is aiding in the growth of atherectomy devices is the growing demand for minimally invasive devices and procedures. This can be attributed to the realization of advantages associated with minimally invasive approaches such as faster healing time and significantly less trauma compared to conventional techniques. Atherectomy devices such as directional atherectomy are considered to be a minimally invasive treatment and have been reported to provide a distinct advantage in the removal of obstructive intima hyperplastic or atherosclerotic lesions without the involvement of implantable devices such as stents. Furthermore, atherectomy devices help in avoiding disadvantages associated with surgical procedures such as surgical scarring and inflammation after stent implantation. Therefore, the advantages offered by atherectomy systems are expected to further drive the growth of atherectomy devices during the forecast period.
Moreover, the ongoing strategic activities among the key market players and technological advancement are further boosting the overall market of atherectomy devices across the globe. For instance, in September 2024, AngioDynamics, Inc., a leading medical technology company, announced that it had received European CE Mark approval for its Auryon Atherectomy System, an innovative device for treating Peripheral Artery Disease (PAD), including Critical Limb Ischemia (CLI) and In-Stent Restenosis (ISR).
Therefore, the factors mentioned above are expected to boost the overall market of atherectomy devices across the globe during the forecast period.
However, the atherectomy procedures can lead to complications such as vessel perforation, embolization, or dissection and stringent regulatory concerns for product approvals may hinder the future market of atherectomy devices market growth.
Atherectomy Devices Market Segment Analysis:
Atherectomy Devices Market by Product Type (Directional, Rotational, Photoablative, and Orbital), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of the atherectomy devices market, the orbital category is expected to hold the largest share in the year 2024. Orbital atherectomy devices are significantly boosting the overall market of atherectomy devices due to their unique advantages in treating complex cardiovascular conditions, particularly heavily calcified plaques. These devices use an orbiting mechanism to sand down calcified plaque while maintaining the integrity of the arterial walls, making them highly effective for patients with advanced atherosclerosis. Unlike traditional atherectomy devices, which may struggle with calcified lesions, orbital atherectomy systems provide more precise plaque removal, reducing the risk of arterial damage and allowing for improved blood flow. The ability to handle both peripheral artery disease (PAD) and coronary artery disease (CAD) makes orbital devices versatile and increases their demand across various cardiovascular applications.
Additionally, the technology behind orbital atherectomy allows for minimally invasive procedures, which have gained traction due to shorter recovery times, fewer complications, and less pain for patients. As healthcare providers increasingly seek out safer, more efficient treatment methods, orbital atherectomy systems are becoming a preferred option, driving their adoption in hospitals and clinics worldwide. Furthermore, continuous advancements in device design and operational safety have led to higher procedural success rates, which further enhances their reputation in the market.
Additionally, the increase in strategic activities by the key market players is also boosting the overall market of orbital atherectomy devices across the globe. For instance, in October 2023, Cardio Flow, Inc., a privately held medical device company specializing in minimally invasive devices to treat peripheral artery disease (PAD), announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its FreedomFlow orbital atherectomy peripheral platform.
Hence, all the above-mentioned factors are expected to generate considerable revenue for the segment pushing the overall growth of the global atherectomy devices market during the forecast period.
North America is expected to dominate the overall atherectomy devices market:
Among all regions, North America is projected to hold the largest share of the global atherectomy devices market in 2024. Several key factors are driving this growth, including the rising prevalence of cardiovascular diseases such as coronary heart disease and peripheral arterial disease, along with increasing rates of obesity, hypertension, and diabetes. Additionally, the growing elderly population and rising government initiatives focused on disease awareness and treatment are contributing to the market expansion across the region.
As per the recent data from the Centers for Disease Control and Prevention (CDC, 2024), approximately 4.9% of U.S. adults were diagnosed with coronary heart disease in 2022. Moreover, by 2023, an estimated 12.1 million Americans were projected to have atrial fibrillation (AF). Each year, over 795,000 people in the U.S. suffer a stroke, with around 610,000 of these being first-time occurrences. Notably, nearly 185,000 strokes about one in four occur in individuals who have previously had a stroke.
The increasing incidence of AF and strokes significantly contributes to the demand for atherectomy devices. AF elevates the risk of blood clot formation, which can lead to atherosclerosis and subsequent stroke conditions requiring the removal of arterial plaque to restore proper blood flow. Atherectomy devices play a critical role in treating these vascular complications by removing blockages, particularly in AF patients who are more prone to such conditions.
Diabetes is another major contributor to the rising demand for atherectomy devices. Elevated blood glucose levels in diabetic patients can accelerate plaque buildup in the arteries, resulting in narrowing or blockages. According to the CDC (2024), an estimated 38.4 million people in the U.S. 11.6% of the total population had diabetes, with 38 million of them aged 18 and older (14.7% of U.S. adults). If left untreated, diabetes can reduce blood flow to the lower extremities and increase the risk of ulcers, infections, and even amputations. Atherectomy devices are vital in restoring proper circulation by clearing arterial blockages in diabetic patients, thereby supporting market growth.
In addition, extensive product development activities in North America, especially in the United States, are further driving market demand. For instance, in October 2023, Cardio Flow, Inc. announced it had received FDA 510(k) clearance for its FreedomFlow(TM) Orbital Atherectomy Peripheral Platform, designed to treat peripheral artery disease (PAD).
In summary, the combination of high disease burden, a large at-risk population, supportive government initiatives, and technological advancements is expected to significantly boost the North American atherectomy devices market during the forecast period.
Atherectomy Devices Market Key Players:
Some of the key market players operating in the atherectomy devices market include Koninklijke Philips N.V., Medtronic PLC, Boston Scientific Corporation, AngioDynamics Inc., Cardiovascular Systems Inc., Avinger, BD, Ra Medical Systems, REX Medical, Cardio Flow, Inc., and others.
Recent Developmental Activities in the Atherectomy Devices Market:
Key takeaways from the atherectomy devices market report study:
Target audience who can benefit from this atherectomy devices market report study:
Frequently Asked Questions for the Atherectomy Devices Market: